1. Nat. Rev. Cardiol. doi:10.1038/nrcardio.2017.18
Figure 5 Proposed algorithm for the choice of antithrombotic therapy in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI)
Figure 5 | Proposed algorithm for the choice of antithrombotic therapy in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI). *Clinical factors known to be associated with increased risk of bleeding are: history of bleeding, oral anticoagulant therapy, female sex, advanced age, low body weight, chronic kidney disease, diabetes mellitus, anaemia, chronic steroid or nonsteroidal anti-inflammatory drug therapy151. ‡Shorter dual antiplatelet therapy (DAPT; 6 months) can be considered in patients with overt bleeding or who are at high risk of bleeding, whereas prolonging DAPT beyond 12 months is a reasonable option in selected patients at low risk of bleeding or without overt bleeding while receiving DAPT. §Vorapaxar and low-dose rivaroxaban have not been tested as adjunctive therapy to prasugrel or ticagrelor. GPI, glycoprotein IIb/IIIa inhibitor; LD, loading dose; PCI, percutaneous coronary intervention; UFH, unfractionated heparin.
Franchi, F. et al. (2017) Antithrombotic therapy for patients with STEMI undergoing primary PCI
Nat. Rev. Cardiol. doi: /nrcardio